Health and Fitness Health and Fitness
Tue, February 28, 2012
[ Tue, Feb 28th 2012 ] - Market Wire
Alere to Acquire eScreen, Inc.
[ Tue, Feb 28th 2012 ] - Market Wire
ICON Acquires PriceSpective
Mon, February 27, 2012
Sat, February 25, 2012
Fri, February 24, 2012
[ Fri, Feb 24th 2012 ] - Market Wire
BrainStorm Featured on CNBC
Thu, February 23, 2012
[ Thu, Feb 23rd 2012 ] - Market Wire
00 am ET
Wed, February 22, 2012
Tue, February 21, 2012
Mon, February 20, 2012
Sat, February 18, 2012
Fri, February 17, 2012
Thu, February 16, 2012
Wed, February 15, 2012

PROLOR Biotech to Present at 2012 Citi Global Health Care Conference


//health-fitness.news-articles.net/content/2012/ .. -at-2012-citi-global-health-care-conference.html
Published in Health and Fitness on Wednesday, February 22nd 2012 at 4:46 GMT by Market Wire   Print publication without navigation


PROLOR Biotech to Present at 2012 Citi Global Health Care Conference -- NES-ZIONA, Israel, Feb. 22, 2012 /PRNewswire/ --

PROLOR Biotech to Present at 2012 Citi Global Health Care Conference

[ ]

NES-ZIONA, Israel, Feb. 22, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: [ PBTH ]), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will give a corporate presentation at the 2012 Citi Global Health Care Conference, being held at the Waldorf Astoria Hotel in New York City.  The presentation is scheduled for February 29, 2012 at 11:30 am ET.

A live webcast of the company's presentation will be available at the Investors section of PROLOR's website at [ www.prolor-biotech.com/?CategoryID=215 ], or at [ http://www.veracast.com/webcasts/citigroup/healthcare2012/53308644.cfm ]. An audio replay of the presentation will be available on the PROLOR website approximately one hour after the presentation and will be archived for at least 30 days.

For more information about the 2012 Citi Global Health Care Conference, visit [ https://www.citievents.com/Metron/forms/MeetingFormFiller.aspx?id=399f0110-1028-4b6b-973f-1512bb7328a9 ].

ABOUT PROLOR 
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins.  PROLOR is currently developing a long-acting version of human growth hormone, which has successfully completed a Phase II clinical trial.  It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, as well as agents for atherosclerosis and rheumatoid arthritis, which are all in preclinical development.  For more information, visit [ www.prolor-biotech.com ]

cellpadding="0" cellspacing="0" id="convertedTable" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">

PROLOR CONTACT:

MEDIA CONTACT:

Shai Novik, President

Barbara Lindheim or Jennifer Anderson

PROLOR Biotech, Inc.

GendeLLindheim BioCom Partners

Tel: +1 866 644-7811

+1 212 584-2276

Email: [ shai@prolor-biotech.com ]

[ blindheim@biocompartners.com ]

SOURCE PROLOR Biotech, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.prolor-biotech.com ]


Publication Contributing Sources